Clinical Trials in New York State

Showing 3481-3500 of 17,167 trials

Evaluation of the Clinical Performance of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses

NCT06377488

This will be an open-label, 3-visit, single-arm, dispensing clinical trial to evaluate visual acuity.

Johnson & Johnson Vision Care, Inc.176 participantsStarted Apr 2024

Jacksonville, Florida, United States • Jacksonville, Florida, United States • Longwood, Florida, United States +12 more locations

Active Not RecruitingPhase 280 miles

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344

The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.

Nonalcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver Disease

GlaxoSmithKline284 participantsStarted Jan 2023

Homewood, Alabama, United States • Chandler, Arizona, United States • Chandler, Arizona, United States +167 more locations

Evaluation of the Clinical Performance of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses

Phase 2b Study of GSK4532990 in Adults With NASH

Find Trials by Condition in New York State

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

CLIP-IT Post-Market Study

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Using Re-inforcement Learning to Automatically Adapt a Remote Therapy Intervention (RTI) for Reducing Adolescent Violence Involvement

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Pediatric Patients Aged 4 to 11 Years With APDS

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

Stryker's Surgeon iD Mandible Reconstruction Plates: A Retrospective Post Market Follow Up